Dianthus Therapeutics Signs Exclusive License Deal With Leads Biolabs For DNTH212, A Phase 1 Ready Bifunctional Autoimmune Drug

+15.07%

Dianthus Therapeutics, Inc. - Common Stock

DNTH

40.85

+15.07%

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function
Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases
DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing
IND cleared by FDA in September 2025 and expected to clear in China in Q4'25. Phase 1 study of DNTH212 expected to initiate in Q4'25 with top-line results in healthy volunteers in 2H'26
Pro forma estimated cash of ~$525 million; reaffirms runway into 2028
Investor conference call and webcast to be held today at 8:00 a.m. ET

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.